Krebs Biochemicals and Industries DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	1.00×	1.00×	1.00×	1.00×	1.00×
	1.66×	1.43×	1.24×	1.27×	1.11×
	−30.0%	−50.0%	−50.1%	−30.7%	−42.8%
	0.14×	0.14×	0.25×	0.29×	0.29×
	−0.93×	−1.00×	−1.16×	−1.49×	−1.76×
	6.5%	10.0%	18.0%	17.0%	24.2%
	11.0%	11.0%	20.3%	18.0%	28.3%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

KREBSBIO₹57.93

Krebs Biochemicals and Industries Limited

· Pharma & Health

₹ CrorePeersALPA BALPHARMA VINEETLAB NATCAPSUQ BIOFILCHEM NECLIFE MANGALAM AAREYDRUGSMcap ₹125 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	1.00	1.00	1.00	1.00	1.00
Interest Burden (Pretax/EBIT) ×	1.11	1.27	1.24	1.43	1.66
EBIT Margin %	-42.85	-30.72	-50.14	-50.03	-30.03
Asset Turnover ×	0.29	0.29	0.25	0.14	0.14
Financial Leverage (Assets/Equity) ×	-1.76	-1.49	-1.16	-1.00	-0.93
ROE (5-step product, year-end total equity) %	24.16	16.96	17.97	10.02	6.48
ROE (owners' profit / average owners' equity) %	28.29	18.04	20.30	10.96	10.96

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.